Cho Han Joo, Kim Hyoung Seok, Yoo Seul Gi, Han Jung Il, Lew Young Ju, Cho Sung Won, Lee Tae Gon, Kim Jong Woo
Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, Seoul, South Korea.
Department of Ophthalmology, Kim's Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, Seoul, South Korea.
Am J Ophthalmol. 2015 Nov;160(5):1000-1005.e2. doi: 10.1016/j.ajo.2015.07.023. Epub 2015 Jul 22.
To evaluate the incidence and associated risk factors of retinal pigment epithelium (RPE) tears after intravitreal ranibizumab injection treatment for retinal angiomatous proliferation (RAP).
Retrospective, observational case series.
Ninety-eight treatment-naïve RAP eyes (86 patients) that received intravitreal ranibizumab injections were included. All patients were treated with an initial series of 3 monthly loading injections, followed by further injections as required. Baseline characteristics and features were evaluated as potential risk factors for RPE tearing. The visual and anatomic outcomes after treatment were evaluated at 12 months from baseline.
RPE tears had developed in 8.2% (8) of the eyes by 12 months. Of these, all had pigment epithelium detachment (PED) at baseline, and the majority (7) had developed an RPE tear within 3 months. Multiple regression analysis showed that higher PED (odds ratio [OR] = 1.411, 95% confidence interval [CI] = 1.199-1.888, P = .011) and thinner choroid (OR = 0.815, 95% CI = 0.719-0.912, P = .023) were associated with a higher risk of RPE tearing. The mean best-corrected visual acuity of the patients with RPE tearing (0.56 ± 0.49 logarithm of the minimal angle of resolution [logMAR]) was significantly worse at 12 months than that of patients without RPE tearing (0.74 ± 0.55 logMAR, P = .009) after treatment.
RPE tears developed in 8.2% of eyes with RAP during the 12 months following ranibizumab injections. Higher PED height and thinner subfoveal choroidal thickness were associated with the development of RPE tears after ranibizumab treatment for RAP.
评估玻璃体内注射雷珠单抗治疗视网膜血管瘤样增生（RAP）后视网膜色素上皮（RPE）撕裂的发生率及相关危险因素。
回顾性观察病例系列。
纳入98只初治的RAP患眼（86例患者），这些患眼接受了玻璃体内雷珠单抗注射。所有患者均接受了最初一系列的3次每月一次的负荷注射，随后根据需要进行进一步注射。评估基线特征和特点作为RPE撕裂的潜在危险因素。从基线起12个月时评估治疗后的视力和解剖学结果。
到12个月时，8.2%（8只）患眼发生了RPE撕裂。其中，所有患眼在基线时均有色素上皮脱离（PED），且大多数（7只）在3个月内发生了RPE撕裂。多元回归分析显示，较高的PED（比值比[OR]=1.411，95%置信区间[CI]=1.199-1.888，P=.011）和较薄的脉络膜（OR=0.815，95%CI=0.719-0.912，P=.023）与RPE撕裂的较高风险相关。治疗后12个月时，发生RPE撕裂的患者的平均最佳矫正视力（最小分辨角对数[logMAR]为0.56±0.49）明显差于未发生RPE撕裂的患者（0.74±0.55 logMAR，P=.009）。
在雷珠单抗注射后的12个月内，8.2%的RAP患眼发生了RPE撕裂。较高的PED高度和较薄的黄斑下脉络膜厚度与雷珠单抗治疗RAP后RPE撕裂的发生相关。
